Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Kabilan K L: Key Nursing Considerations for Abciximab Therapy
Kabilan K L/LinkedIn
May 28, 2026, 12:36

Kabilan K L: Key Nursing Considerations for Abciximab Therapy

Kabilan K. L., Pediatric Cardiac ICU Nurse at Alemeis Hospital, shared a post on LinkedIn:

“455 | Abciximab (Abcixirel)

Abciximab is a monoclonal antibody antiplatelet agent used intravenously in high-risk patients undergoing PCI.

Mechanism of action

  • Fab fragment of immunoglobulin
  • Blocks glycoprotein IIb/IIIa receptors on platelets
  • Inhibits platelet aggregation
  • Helps prevent thrombus formation

Indication

  • Used as an adjunct with aspirin and heparin
  • High-risk patients undergoing percutaneous coronary intervention (PCI)
  • Effects may last 24–48 hours after infusion

Dosage

  • Initial loading: 250 mcg/kg IV bolus
  • Infusion before angioplasty: 125 ng/kg/min, max 10 mcg/min
  • Infusion after angioplasty: continue as per protocol, commonly up to 12 hours

Side effects

  • Bleeding
  • Hypotension
  • Nausea
  • Bradycardia
  • Rare thrombocytopenia

Nursing responsibilities

  • Monitor for bleeding from IV site, gums, urine, stool, and puncture sites
  • Check platelet count and coagulation profile as ordered
  • Monitor BP, HR, and ECG
  • Avoid unnecessary IM injections
  • Apply firm pressure after sheath removal
  • Educate patient to report bleeding, dizziness, or black stools

Key point

Abciximab is a potent antiplatelet drug for high-risk PCI patients.

Use with caution and monitor closely for bleeding.

Stay Consistent!”

Kabilan K L: Key Nursing Considerations for Abciximab Therapy

Stay updated with Hemostasis Today.

Abciximab Abcixirel Health Hematology Hemostasis Hemostasis News Hemostasis Today Kabilan K. L Medicine PCI
NewsFeed